TheraSphere

DEVICE15 trials

Sponsors

University of California, Irvine, Stanford University, Sidney Kimmel Cancer Center at Thomas Jefferson University, Boston Scientific Corporation, Emory University

Conditions

Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerColorectal Cancer MetastaticHepatocellular CarcinomaHepatocellular Carcinoma (HCC)Immune Checkpoint InhibitorInternal RadiotherapyLiver Cancer

Early Phase 1

Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery

CompletedNCT02072356

Ohio State University Comprehensive Cancer CenterAdult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer +1

Start: 2010-10-11End: 2021-06-15Updated: 2022-09-30

Phase 1

Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease

WithdrawnNCT01864070

M.D. Anderson Cancer CenterLiver Cancer

Start: 2014-05-31Updated: 2014-07-22

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

RecruitingNCT04518748

University of Michigan Rogel Cancer CenterLiver Malignancy

Start: 2020-09-16End: 2028-11-30Target: 70Updated: 2025-08-05

Phase 2

Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer

Federation Francophone de Cancerologie DigestiveImmune Checkpoint Inhibitor, Internal Radiotherapy, Metastatic Colorectal Cancer +2

Start: 2020-10-07End: 2024-10-31Target: 52Updated: 2023-08-18

Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria

RecruitingNCT06773845

Seoul National University HospitalHepatocellular Carcinoma (HCC), Radioembolization

Start: 2025-03-11End: 2029-12-31Target: 100Updated: 2025-06-17

Unknown Phase

TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma

University of California, IrvineHepatocellular Carcinoma, Liver Cancer, Liver Neoplasm +1

Updated: 2024-01-08

A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma

Stanford UniversityLiver Cancer

Updated: 2021-04-01

TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma

CompletedNCT01349075

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityHepatocellular Carcinoma

Start: 2007-10-31End: 2021-03-15Updated: 2025-04-29

Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer

CompletedNCT01483027

Boston Scientific CorporationColorectal Cancer Metastatic

Start: 2012-01-31End: 2020-08-31Updated: 2022-03-29

TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis

CompletedNCT01556282

Emory UniversityLiver Cancer, Portal Vein Thrombosis

Start: 2009-03-31End: 2014-01-31Updated: 2014-05-28

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

CompletedNCT01556490

Boston Scientific CorporationUnresectable Hepatocellular Carcinoma

Start: 2012-03-31End: 2022-04-30Updated: 2023-11-08

A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCC

CompletedNCT03295006

Boston Scientific CorporationHepatocellular Carcinoma

Start: 2016-10-31End: 2020-12-01Updated: 2021-04-21

Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)

CompletedNCT04069468

Boston Scientific CorporationHepatocellular Carcinoma

Start: 2019-03-13End: 2024-12-31Updated: 2025-07-23

TheraSphere & Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer

CompletedNCT04090645

Methodist Health SystemLiver, Cancer of, Non-Resectable

Start: 2014-05-22End: 2021-04-16Updated: 2021-11-11

Transarterial Radioembolization (TARE) in COlorectal MEtastasis of Liver

CompletedNCT06030232

Ankara UniversityTransarterial Radioembolization

Start: 2024-01-15End: 2024-04-15Updated: 2024-04-24

Related Papers

PROACTIF: Final results from the largest prospective real-world study of 1196 primary liver cancer patients (PLC) treated with yttrium-90 (Y90) glass transarterial radioembolization (TARE).

Journal of Clinical Oncology2026-01-10

Sequential <sup>90</sup>Y Selective Internal Radiation Therapy (SIRT) and Stereotactic Body Radiation Therapy (SBRT) using <sup>90</sup>Y PET-based Absorbed Dose Maps: Interim Analysis of a Phase 1 Study.

2025-02-222 citations

Utility of pre-procedural [<sup>99m</sup>Tc]TcMAA SPECT/CT Multicompartment Dosimetry for Treatment Planning of <sup>90</sup>Y Glass microspheres in patients with Hepatocellular Carcinoma: comparison of anatomic versus [<sup>99m</sup>Tc]TcMAA-based Segmentation.

2024-09-27

Optimal patient selection for yttrium-90 glass plus chemotherapy in the treatment of colorectal liver metastases: additional quality of life, efficacy, and safety analyses from the EPOCH study

The Oncologist2024-07-103 citations

Direct comparison and reproducibility of two segmentation methods for multicompartment dosimetry: round robin study on radioembolization treatment planning in hepatocellular carcinoma.

2023-09-124 citations

The EPOCH trial: Identifying key patient subgroups to optimize treatment planning.

Journal of Clinical Oncology2023-01-24

A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study

European Journal of Nuclear Medicine and Molecular Imaging2022-04-0881 citations

Radioembolization with chemotherapy for liver-dominant colorectal cancer: Time to subsequent treatment and quality of life in the EPOCH trial.

Journal of Clinical Oncology2022-01-192 citations

Radioembolization with chemotherapy for liver-dominant colorectal cancer: Analysis of patient subgroups in the EPOCH trial.

Journal of Clinical Oncology2022-01-19

Evaluating the Effectiveness of Yttrium-90 Glass Microspheres in the Treatment of Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and Metastatic Colorectal Cancer in Practice: Protocol for the Prospective PROACTIF Phase IV Registry Study in France.

2021-11-184 citations

A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma

Journal of Hepatocellular Carcinoma2021-09-0111 citations

TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial.

2019-01-1719 citations

Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.

2018-08-1526 citations

Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization

BMC Cancer2018-01-1228 citations

A phase III clinical trial of intra-arterial yttrium-90 glass microspheres in the treatment of patients with unresectable hepatocellular carcinoma.

Journal of Clinical Oncology2015-01-20

Phase 3 clinical Trial Evaluating <sup>90</sup>y glass microspheres in patients with metastatic colorectal carcinoma of the liver who have failed first-line chemotherapy.

Journal of Clinical Oncology2015-01-20

Multicenter Phase II Study of Sequential Radioembolization-Sorafenib Therapy for Inoperable Hepatocellular Carcinoma

PLoS ONE2014-03-1067 citations